Seattle researchers to engineer kidney tissue chip for predicting drug safety

July 25, 2012 By Leila Gray
Seattle researchers to engineer kidney tissue chip for predicting drug safety
An example of a tissue chip for drug safety testing. Credit: NCATS

(Medical Xpress) -- Seattle researchers will be part of the new federal initiative to engineer 3-dimensional chips containing living cells and tissues that imitate the structure and function of human organs.  These tissue chips will be used for drug safety testing.

Tissue chips merge techniques from the computer industry with those from bioengineering by combining miniature models of living organ tissues onto a transparent microchip. Ranging in size from a coin to a house key, the chips are lined with living cells and contain features designed to replicate the complex biological function of a specific organ.

The Seattle team will design, implement and test a tissue-engineered human kidney microphysiological system.  Kidneys, which clear the blood of waste products, are among the sensitive organs that can be damaged by certain medications, environmental toxins or an excess of natural substances produced by the body.

The Seattle project, announced July 24, is led by Dr. Jonathan Himmelfarb, University of Washington professor of medicine in the Department of Medicine, Division of Nephrology, and director of the Kidney Research Institute.  The project team consists of physicians, bioengineers, pharmacists, environmental health researchers, and pharmaceutical developers from the UW schools of medicine, public health and pharmacy, and the College of Engineering. The amount  and years of of funding to the UW are yet to be announced, pending Notice of Grant Award. Overall, the national initiative is budgeted at $70 million.

Their project proposal is one of 17 nationwide funded in a recent round of awards from the new National Center for Advancing Translational Sciences of the National Institutes of Health.  This grant program, a collaboration with the Defense Advanced Research Projects Agency and the U.S. Food and Drug Administration, was created to improve methods for predicting whether newly developed drugs will be safe in humans.

The goal is to develop human tissue chips that simulate  the structure and function of human organs, such the lung, heart, liver, and kidneys.  Scientists could then use these tissue chips to test drug candidates and predict their safety before the next step, human drug studies. This approach is expected be more rapid and cost effective than those currently available.

The NIH pointed to studies that show that more than 30 percent of promising medications have failed in human clinical trials because the drugs were found to be toxic, despite pre-clinical studies in animal models. Tissue chips may offer more accurate predictions of the side effects of potential therapeutic agents because they contain human cells.

Ten of the 17 new awards will support studies to design 3-dimensional cellular microsystems that represent different . These bioengineered devices will produce relevant physiological functions and will reflect the complexity and diversity of living organs, including genetic differences, disease complexity and pharmacological responses.  The additional seven National Center for Advancing Translational Sciences awards will explore the potential of stem cells and progenitor cells to form the many cell types that make up the architecture of complex organs. These could be a source of cells to populate tissue chips.

Himmelfarb and his colleagues propose to create a tiny, 3-dimensional lab device containing engineered biological tissues that will perform certain actions of a living human kidney.  The system would evaluate the uptake, breakdown and elimination of potentially toxic substances, and predict the rate for these chemical reactions. The system might also help assess kidney injury from infections disease organisms and from toxins, both those introduced into the body and those produced by the body.

The micro-model of kidney physiology will also feature two parallel structures – small blood vessels and the surface lining of the renal tubules.  This aspect of the device will enable researchers to study the complex interactions between these two structures, which are normally in intimate association inside each of the functional units of the kidney, the nephrons.

In addition to Himmelfarb, the UW project team includes Jeremy Duffield from the Department of Medicine, Division of Nephrology; Ying Zheng from the Department of Bioengineering; Ken Thummel and Joanne Wang from the Department of Pharmaceutics; David Eaton, of the Department of Environmental and Occupational Health and the UW Center for Ecogentics and Environmental Health, and Danny Shen from the Department of Pharmacy.

Nortis Inc., a bioengineering start-up company funded through  the UW’s Center for Commercialization, will also be a partner in the project. Thomas Neumann is president and CEO of Nortis.  Project plans include using the Life Sciences Development Fund-supported Washington Phenotype Biospecimen Resource to obtain specimens for the project.

Explore further: Lab-engineered kidney project reaches early milestone

Related Stories

Lab-engineered kidney project reaches early milestone

June 21, 2012
Regenerative medicine researchers at Wake Forest Baptist Medical Center have reached an early milestone in a long-term project that aims to build replacement kidneys in the lab to help solve the shortage of donor organs.

Success in growing functional pituitary gland in a lab culture will advance regenerative medicine

March 2, 2012
Embryonic stem cells grown in a laboratory culture can organize themselves into a partial pituitary gland that is fully functional when transplanted into mice, a team of researchers led by Yoshiki Sasai of the RIKEN Center ...

Scientists produce eye structures from human blood-derived stem cells

March 14, 2012
(Medical Xpress) -- For the first time, scientists at the University of Wisconsin-Madison have made early retina structures containing proliferating neuroretinal progenitor cells using induced pluripotent stem (iPS) cells ...

Recommended for you

New understanding of how muscles work

August 23, 2017
Muscle malfunctions may be as simple as a slight strain after exercise or as serious as heart failure and muscular dystrophy. A new technique developed at McGill now makes it possible to look much more closely at how sarcomeres, ...

Scientists find RNA with special role in nerve healing process

August 22, 2017
Scientists may have identified a new opening to intervene in the process of healing peripheral nerve damage with the discovery that an "anti-sense" RNA (AS-RNA) is expressed when nerves are injured. Their experiments in mice ...

Mouse model of human immune system inadequate for stem cell studies

August 22, 2017
A type of mouse widely used to assess how the human immune system responds to transplanted stem cells does not reflect what is likely to occur in patients, according to a study by researchers at the Stanford University School ...

Researchers offer new targets for drugs against fatty liver disease and liver cancer

August 22, 2017
There may no silver bullet for treating liver cancer or fatty liver disease, but knowing the right targets will help scientists develop the most effective treatments. Researchers in Sweden have just identified a number of ...

Bio-inspired materials give boost to regenerative medicine

August 18, 2017
What if one day, we could teach our bodies to self-heal like a lizard's tail, and make severe injury or disease no more threatening than a paper cut?

Make way for hemoglobin

August 18, 2017
Every cell in the body, whether skin or muscle or brain, starts out as a generic cell that acquires its unique characteristics after undergoing a process of specialization. Nowhere is this process more dramatic than it is ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.